TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02558764

Intervention type: DEVICE
Group type: OTHER
Intervention: portable (pocket) negative pressure wound treatment device
Description: PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
Study: NCT02900248

Intervention type: OTHER
Intervention: Provider determined
Description: Provider will treat patient as he/she feels best
Study: NCT02360722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Education
Description: Two nutritional education courses at baseline and 3 months after intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Education
Description: Two nutritional education courses at baseline and 3 months after intervention
Study: NCT03813277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: infusion
Study: NCT05022433

Intervention type: PROCEDURE
Intervention: UVC insertion
Description: To compare two formulae namely UN-1 and Shukla method to estimate the UVC insertion length in achieving optimum UVC tip position.

Intervention type: PROCEDURE
Intervention: UVC insertion
Description: To compare two formulae namely UN-1 and Shukla method to estimate the UVC insertion length in achieving optimum UVC tip position.
Study: NCT04000984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Training (MBT) Program
Description: Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation Training
Description: Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
Study: NCT02878447

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
Study: NCT04011488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Tool
Description: We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes.
Study: NCT03055962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT00256022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Probiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Probiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Powder
Study: NCT02630875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A4250
Description: A4250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A4250
Description: A4250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A4250
Description: A4250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A4250
Description: A4250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A4250
Description: A4250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A4250
Description: A4250
Study: NCT03390595

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: avelumab 10mg/kg with carboplatin/gemcitabine
Description: Dosage and schedule:~* Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~  * Intravenously every 2 weeks for two cycles.~ * During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~ * Intravenously every 2 weeks until progressive disease or intolerance.~* Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~  * Carboplatin 5AUC day +1.~ * Gemcitabine 1000mg/m2 day +1 and +8.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin/gemcitabine alone
Description: •Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~* Carboplatin 5AUC day +1.~* Gemcitabine 1000mg/m2 day +1 and +8.
Study: NCT01358292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semi-extended Surgical Technique
Description: Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
Study: NCT00966121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation
Description: * Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBL+Propranolol
Description: * Start with 20 mg b.i.d~* Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
Study: NCT02057211

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous mesenchymal stem cell transplantation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham transplantation of mesenchymal stem cells
Description: Placebo control for transplantation of mesenchymal stem cells
Study: NCT03289351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin, Tazobactam Drug Combination
Description: Single drug therapy
Study: NCT01258257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of a lumbar drain
Description: In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
Study: NCT03901716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Patients in Group S received sufentanil 0.1 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients in Group F received fentanyl 1 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
Study: NCT01725126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2890457
Description: Provided as powder and capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2890457
Description: Provided as powder and capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2890457
Description: Provided as powder and capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided as powder and Capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided as powder and Capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided as powder and Capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only
Study: NCT01358292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Surgical Technique
Description: Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
Study: NCT04346199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib- administered orally
Study: NCT00560846

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact
Description: Preoperative 5 day oral Impact and early post-operative enteral Impact

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose load
Description: Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
Study: NCT04175561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green prescription
Description: Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
Study: NCT03414385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Acute bout of aerobic exercise at moderate intensity for 2 hours
Study: NCT00677534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 50,000 Units PO Twice weekly for 8 weeks
Study: NCT02518035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone Gel
Description: Silicone gel will be applied twice per day in the experimental group
Study: NCT04055090

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Long-Term Follow-Up of Patients who Received Engensis (VM202)
Description: No study drug is administered in this study. Patients who received Engensis (VM202) in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Long-Term Follow-Up of Patients who Received Placebo
Description: No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
Study: NCT03106753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: intrathecal bupivacaine 7.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intrathecal bupivacaine 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: 0.25 mg Terbutaline subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline
Description: 0.25 mg Terbutaline subcutaneously
Study: NCT00974194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Trocar CCK
Description: CCK using Triport

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CCK
Description: CCK using three or four ports
Study: NCT03147703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Timing
Description: the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Timing
Description: the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
Study: NCT04991376

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-specific miRNA levels
Description: Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-specific miRNA levels
Description: Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-specific miRNA levels
Description: Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.
Study: NCT00509249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01417624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMR Guidance in terms of guiding LV lead implantation
Description: Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CMR Guidance in terms of guiding LV lead implantation
Description: Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only.
Study: NCT05765305

Intervention type: DRUG
Intervention: Letrozole with chromium
Description: Letrozole versus letrozole with chromium
Study: NCT02997826

Intervention type: OTHER
Group type: OTHER
Intervention: Infantil formula
Study: NCT01527747

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg daily
Study: NCT03342274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Program
Description: Participants will receive group weight loss sessions addressing healthy eating, exercise, and weight loss principles adapted from the Diabetes Prevention Program delivered by Community Health Workers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.
Study: NCT01616004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N2O
Study: NCT01320241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-expandable 125I radioactive seeds-loaded-stent
Description: Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-expandable biliary nitinol alloys stent
Description: Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
Study: NCT01616004

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Air
Description: sham comparator
Study: NCT02600390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: A two-hour infusion provided once a week over a 4-week or 6-week period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: A two-hour infusion provided once a week over a 4-week or 6-week period.
Study: NCT03840005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursonorm
Description: Ursodeoxycholic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursonorm
Description: Ursodeoxycholic acid
Study: NCT00304304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education
Description: Research assistant worked with CCC staff on asthma prevention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma education
Description: Research assistant worked with CCC staff on asthma prevention
Study: NCT00895557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chantix
Description: .5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
Study: NCT02716636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow placement of the tenaculum
Description: Slow placement of the tenaculum on the cervix
Study: NCT01236638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
Study: NCT03046121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered Function-focused Care (Fam-FFC)
Description: An educational empowerment model for family CGs that includes a care pathway, provided within a social-ecological in-patient framework promoting specialized care to patients with ADRD. The intervention creates an enabling milieu for the person with ADRD through environmental and policy assessment/modification, staff education, unit-based champions, and individualized goal setting that focuses on functional recovery during hospitalization and the immediate post-acute period.
Study: NCT02306551

Intervention type: OTHER
Intervention: Biological and psycho-social risk and resilience factors
Description: Naturalistic study, no active intervention or exposure is administered

Intervention type: OTHER
Intervention: Biological and psycho-social risk and resilience factors
Description: Naturalistic study, no active intervention or exposure is administered

Intervention type: OTHER
Intervention: Biological and psycho-social risk and resilience factors
Description: Naturalistic study, no active intervention or exposure is administered

Intervention type: OTHER
Intervention: Biological and psycho-social risk and resilience factors
Description: Naturalistic study, no active intervention or exposure is administered
Study: NCT01224977

Intervention type: DRUG
Group type: OTHER
Intervention: azithromycin
Description: azithromycin 500 mg 3/week for 3 months
Study: NCT00569114

Intervention type: DRUG
Group type: OTHER
Intervention: TG01
Description: Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
Study: NCT00799032

Intervention type: DEVICE
Group type: OTHER
Intervention: PCI
Description: coronary stent implantation